Global Bupivacaine Extended-Release Liposome Injection Market Growth 2025-2031--LP INFORMATION, INC.

Global Bupivacaine Extended-Release Liposome Injection Market Growth 2025-2031

Product Code: 1562443

Industry: Pharma & Healthcare

Published: May 15,2025

Pages: 77

Delivery Time: 2-3 business days

Global Bupivacaine Extended-Release Liposome Injection Market Growth 2025-2031

Product Code: 1562443

Industry: Pharma & Healthcare

Published: May 15,2025

Pages: 77

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

The global Bupivacaine Extended-Release Liposome Injection market size is predicted to grow from US$ 364 million in 2025 to US$ 481 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Bupivacaine liposome injection is a special formulation that encapsulates the local anesthetic bupivacaine within liposomes. This delivery system allows for prolonged and controlled release of bupivacaine, thereby extending the duration of its anesthetic effect.

United States market for Bupivacaine Extended-Release Liposome Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Bupivacaine Extended-Release Liposome Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Bupivacaine Extended-Release Liposome Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Bupivacaine Extended-Release Liposome Injection players cover Pacira Pharmaceuticals, Jiangsu Hengrui Pharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Bupivacaine Extended-Release Liposome Injection Industry Forecast” looks at past sales and reviews total world Bupivacaine Extended-Release Liposome Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Bupivacaine Extended-Release Liposome Injection sales for 2025 through 2031. With Bupivacaine Extended-Release Liposome Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bupivacaine Extended-Release Liposome Injection industry.

This Insight Report provides a comprehensive analysis of the global Bupivacaine Extended-Release Liposome Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bupivacaine Extended-Release Liposome Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bupivacaine Extended-Release Liposome Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bupivacaine Extended-Release Liposome Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bupivacaine Extended-Release Liposome Injection.

This report presents a comprehensive overview, market shares, and growth opportunities of Bupivacaine Extended-Release Liposome Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    133mg Per Vial

    266mg Per Vial

Segmentation by Application:

    Local Anesthesia

    Postoperative Analgesia

    Other

This report also splits the market by region:

    Americas

    United States

    Canada

    Mexico

    Brazil

    APAC

    China

    Japan

    Korea

    Southeast Asia

    India

    Australia

    Europe

    Germany

    France

UK

    Italy

    Russia

    Middle East & Africa

    Egypt

    South Africa

    Israel

    Turkey

    GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

    Pacira Pharmaceuticals

    Jiangsu Hengrui Pharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bupivacaine Extended-Release Liposome Injection market?

What factors are driving Bupivacaine Extended-Release Liposome Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bupivacaine Extended-Release Liposome Injection market opportunities vary by end market size?

How does Bupivacaine Extended-Release Liposome Injection break out by Type, by Application?

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Bupivacaine Extended-Release Liposome Injection Annual Sales 2020-2031
        2.1.2 World Current & Future Analysis for Bupivacaine Extended-Release Liposome Injection by Geographic Region, 2020, 2024 & 2031
        2.1.3 World Current & Future Analysis for Bupivacaine Extended-Release Liposome Injection by Country/Region, 2020, 2024 & 2031
    2.2 Bupivacaine Extended-Release Liposome Injection Segment by Type
        2.2.1 133mg Per Vial
        2.2.2 266mg Per Vial
    2.3 Bupivacaine Extended-Release Liposome Injection Sales by Type
        2.3.1 Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2025)
        2.3.2 Global Bupivacaine Extended-Release Liposome Injection Revenue and Market Share by Type (2020-2025)
        2.3.3 Global Bupivacaine Extended-Release Liposome Injection Sale Price by Type (2020-2025)
    2.4 Bupivacaine Extended-Release Liposome Injection Segment by Application
        2.4.1 Local Anesthesia
        2.4.2 Postoperative Analgesia
        2.4.3 Other
    2.5 Bupivacaine Extended-Release Liposome Injection Sales by Application
        2.5.1 Global Bupivacaine Extended-Release Liposome Injection Sale Market Share by Application (2020-2025)
        2.5.2 Global Bupivacaine Extended-Release Liposome Injection Revenue and Market Share by Application (2020-2025)
        2.5.3 Global Bupivacaine Extended-Release Liposome Injection Sale Price by Application (2020-2025)

3 Global by Company
    3.1 Global Bupivacaine Extended-Release Liposome Injection Breakdown Data by Company
        3.1.1 Global Bupivacaine Extended-Release Liposome Injection Annual Sales by Company (2020-2025)
        3.1.2 Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Company (2020-2025)
    3.2 Global Bupivacaine Extended-Release Liposome Injection Annual Revenue by Company (2020-2025)
        3.2.1 Global Bupivacaine Extended-Release Liposome Injection Revenue by Company (2020-2025)
        3.2.2 Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Company (2020-2025)
    3.3 Global Bupivacaine Extended-Release Liposome Injection Sale Price by Company
    3.4 Key Manufacturers Bupivacaine Extended-Release Liposome Injection Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Bupivacaine Extended-Release Liposome Injection Product Location Distribution
        3.4.2 Players Bupivacaine Extended-Release Liposome Injection Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.6 New Products and Potential Entrants
    3.7 Market M&A Activity & Strategy

4 World Historic Review for Bupivacaine Extended-Release Liposome Injection by Geographic Region
    4.1 World Historic Bupivacaine Extended-Release Liposome Injection Market Size by Geographic Region (2020-2025)
        4.1.1 Global Bupivacaine Extended-Release Liposome Injection Annual Sales by Geographic Region (2020-2025)
        4.1.2 Global Bupivacaine Extended-Release Liposome Injection Annual Revenue by Geographic Region (2020-2025)
    4.2 World Historic Bupivacaine Extended-Release Liposome Injection Market Size by Country/Region (2020-2025)
        4.2.1 Global Bupivacaine Extended-Release Liposome Injection Annual Sales by Country/Region (2020-2025)
        4.2.2 Global Bupivacaine Extended-Release Liposome Injection Annual Revenue by Country/Region (2020-2025)
    4.3 Americas Bupivacaine Extended-Release Liposome Injection Sales Growth
    4.4 APAC Bupivacaine Extended-Release Liposome Injection Sales Growth
    4.5 Europe Bupivacaine Extended-Release Liposome Injection Sales Growth
    4.6 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Growth

5 Americas
    5.1 Americas Bupivacaine Extended-Release Liposome Injection Sales by Country
        5.1.1 Americas Bupivacaine Extended-Release Liposome Injection Sales by Country (2020-2025)
        5.1.2 Americas Bupivacaine Extended-Release Liposome Injection Revenue by Country (2020-2025)
    5.2 Americas Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025)
    5.3 Americas Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Bupivacaine Extended-Release Liposome Injection Sales by Region
        6.1.1 APAC Bupivacaine Extended-Release Liposome Injection Sales by Region (2020-2025)
        6.1.2 APAC Bupivacaine Extended-Release Liposome Injection Revenue by Region (2020-2025)
    6.2 APAC Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025)
    6.3 APAC Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan

7 Europe
    7.1 Europe Bupivacaine Extended-Release Liposome Injection by Country
        7.1.1 Europe Bupivacaine Extended-Release Liposome Injection Sales by Country (2020-2025)
        7.1.2 Europe Bupivacaine Extended-Release Liposome Injection Revenue by Country (2020-2025)
    7.2 Europe Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025)
    7.3 Europe Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Bupivacaine Extended-Release Liposome Injection by Country
        8.1.1 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales by Country (2020-2025)
        8.1.2 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Revenue by Country (2020-2025)
    8.2 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025)
    8.3 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Bupivacaine Extended-Release Liposome Injection
    10.3 Manufacturing Process Analysis of Bupivacaine Extended-Release Liposome Injection
    10.4 Industry Chain Structure of Bupivacaine Extended-Release Liposome Injection

11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Bupivacaine Extended-Release Liposome Injection Distributors
    11.3 Bupivacaine Extended-Release Liposome Injection Customer

12 World Forecast Review for Bupivacaine Extended-Release Liposome Injection by Geographic Region
    12.1 Global Bupivacaine Extended-Release Liposome Injection Market Size Forecast by Region
        12.1.1 Global Bupivacaine Extended-Release Liposome Injection Forecast by Region (2026-2031)
        12.1.2 Global Bupivacaine Extended-Release Liposome Injection Annual Revenue Forecast by Region (2026-2031)
    12.2 Americas Forecast by Country (2026-2031)
    12.3 APAC Forecast by Region (2026-2031)
    12.4 Europe Forecast by Country (2026-2031)
    12.5 Middle East & Africa Forecast by Country (2026-2031)
    12.6 Global Bupivacaine Extended-Release Liposome Injection Forecast by Type (2026-2031)
    12.7 Global Bupivacaine Extended-Release Liposome Injection Forecast by Application (2026-2031)

13 Key Players Analysis
    13.1 Pacira Pharmaceuticals
        13.1.1 Pacira Pharmaceuticals Company Information
        13.1.2 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Product Portfolios and Specifications
        13.1.3 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
        13.1.4 Pacira Pharmaceuticals Main Business Overview
        13.1.5 Pacira Pharmaceuticals Latest Developments
    13.2 Jiangsu Hengrui Pharm
        13.2.1 Jiangsu Hengrui Pharm Company Information
        13.2.2 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Product Portfolios and Specifications
        13.2.3 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales, Revenue, Price and Gross Margin (2020-2025)
        13.2.4 Jiangsu Hengrui Pharm Main Business Overview
        13.2.5 Jiangsu Hengrui Pharm Latest Developments

14 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. Bupivacaine Extended-Release Liposome Injection Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Table 2. Bupivacaine Extended-Release Liposome Injection Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
 Table 3. Major Players of 133mg Per Vial
 Table 4. Major Players of 266mg Per Vial
 Table 5. Global Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025) & (K Units)
 Table 6. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2025)
 Table 7. Global Bupivacaine Extended-Release Liposome Injection Revenue by Type (2020-2025) & ($ million)
 Table 8. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Type (2020-2025)
 Table 9. Global Bupivacaine Extended-Release Liposome Injection Sale Price by Type (2020-2025) & (US$/Unit)
 Table 10. Global Bupivacaine Extended-Release Liposome Injection Sale by Application (2020-2025) & (K Units)
 Table 11. Global Bupivacaine Extended-Release Liposome Injection Sale Market Share by Application (2020-2025)
 Table 12. Global Bupivacaine Extended-Release Liposome Injection Revenue by Application (2020-2025) & ($ million)
 Table 13. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Application (2020-2025)
 Table 14. Global Bupivacaine Extended-Release Liposome Injection Sale Price by Application (2020-2025) & (US$/Unit)
 Table 15. Global Bupivacaine Extended-Release Liposome Injection Sales by Company (2020-2025) & (K Units)
 Table 16. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Company (2020-2025)
 Table 17. Global Bupivacaine Extended-Release Liposome Injection Revenue by Company (2020-2025) & ($ millions)
 Table 18. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Company (2020-2025)
 Table 19. Global Bupivacaine Extended-Release Liposome Injection Sale Price by Company (2020-2025) & (US$/Unit)
 Table 20. Key Manufacturers Bupivacaine Extended-Release Liposome Injection Producing Area Distribution and Sales Area
 Table 21. Players Bupivacaine Extended-Release Liposome Injection Products Offered
 Table 22. Bupivacaine Extended-Release Liposome Injection Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
 Table 23. New Products and Potential Entrants
 Table 24. Market M&A Activity & Strategy
 Table 25. Global Bupivacaine Extended-Release Liposome Injection Sales by Geographic Region (2020-2025) & (K Units)
 Table 26. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share Geographic Region (2020-2025)
 Table 27. Global Bupivacaine Extended-Release Liposome Injection Revenue by Geographic Region (2020-2025) & ($ millions)
 Table 28. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Geographic Region (2020-2025)
 Table 29. Global Bupivacaine Extended-Release Liposome Injection Sales by Country/Region (2020-2025) & (K Units)
 Table 30. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country/Region (2020-2025)
 Table 31. Global Bupivacaine Extended-Release Liposome Injection Revenue by Country/Region (2020-2025) & ($ millions)
 Table 32. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Country/Region (2020-2025)
 Table 33. Americas Bupivacaine Extended-Release Liposome Injection Sales by Country (2020-2025) & (K Units)
 Table 34. Americas Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country (2020-2025)
 Table 35. Americas Bupivacaine Extended-Release Liposome Injection Revenue by Country (2020-2025) & ($ millions)
 Table 36. Americas Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025) & (K Units)
 Table 37. Americas Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025) & (K Units)
 Table 38. APAC Bupivacaine Extended-Release Liposome Injection Sales by Region (2020-2025) & (K Units)
 Table 39. APAC Bupivacaine Extended-Release Liposome Injection Sales Market Share by Region (2020-2025)
 Table 40. APAC Bupivacaine Extended-Release Liposome Injection Revenue by Region (2020-2025) & ($ millions)
 Table 41. APAC Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025) & (K Units)
 Table 42. APAC Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025) & (K Units)
 Table 43. Europe Bupivacaine Extended-Release Liposome Injection Sales by Country (2020-2025) & (K Units)
 Table 44. Europe Bupivacaine Extended-Release Liposome Injection Revenue by Country (2020-2025) & ($ millions)
 Table 45. Europe Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025) & (K Units)
 Table 46. Europe Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025) & (K Units)
 Table 47. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales by Country (2020-2025) & (K Units)
 Table 48. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Country (2020-2025)
 Table 49. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025) & (K Units)
 Table 50. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025) & (K Units)
 Table 51. Key Market Drivers & Growth Opportunities of Bupivacaine Extended-Release Liposome Injection
 Table 52. Key Market Challenges & Risks of Bupivacaine Extended-Release Liposome Injection
 Table 53. Key Industry Trends of Bupivacaine Extended-Release Liposome Injection
 Table 54. Bupivacaine Extended-Release Liposome Injection Raw Material
 Table 55. Key Suppliers of Raw Materials
 Table 56. Bupivacaine Extended-Release Liposome Injection Distributors List
 Table 57. Bupivacaine Extended-Release Liposome Injection Customer List
 Table 58. Global Bupivacaine Extended-Release Liposome Injection Sales Forecast by Region (2026-2031) & (K Units)
 Table 59. Global Bupivacaine Extended-Release Liposome Injection Revenue Forecast by Region (2026-2031) & ($ millions)
 Table 60. Americas Bupivacaine Extended-Release Liposome Injection Sales Forecast by Country (2026-2031) & (K Units)
 Table 61. Americas Bupivacaine Extended-Release Liposome Injection Annual Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 62. APAC Bupivacaine Extended-Release Liposome Injection Sales Forecast by Region (2026-2031) & (K Units)
 Table 63. APAC Bupivacaine Extended-Release Liposome Injection Annual Revenue Forecast by Region (2026-2031) & ($ millions)
 Table 64. Europe Bupivacaine Extended-Release Liposome Injection Sales Forecast by Country (2026-2031) & (K Units)
 Table 65. Europe Bupivacaine Extended-Release Liposome Injection Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 66. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Forecast by Country (2026-2031) & (K Units)
 Table 67. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 68. Global Bupivacaine Extended-Release Liposome Injection Sales Forecast by Type (2026-2031) & (K Units)
 Table 69. Global Bupivacaine Extended-Release Liposome Injection Revenue Forecast by Type (2026-2031) & ($ millions)
 Table 70. Global Bupivacaine Extended-Release Liposome Injection Sales Forecast by Application (2026-2031) & (K Units)
 Table 71. Global Bupivacaine Extended-Release Liposome Injection Revenue Forecast by Application (2026-2031) & ($ millions)
 Table 72. Pacira Pharmaceuticals Basic Information, Bupivacaine Extended-Release Liposome Injection Manufacturing Base, Sales Area and Its Competitors
 Table 73. Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Product Portfolios and Specifications
 Table 74. Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 75. Pacira Pharmaceuticals Main Business
 Table 76. Pacira Pharmaceuticals Latest Developments
 Table 77. Jiangsu Hengrui Pharm Basic Information, Bupivacaine Extended-Release Liposome Injection Manufacturing Base, Sales Area and Its Competitors
 Table 78. Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Product Portfolios and Specifications
 Table 79. Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. Jiangsu Hengrui Pharm Main Business
 Table 81. Jiangsu Hengrui Pharm Latest Developments


List of Figures
 Figure 1. Picture of Bupivacaine Extended-Release Liposome Injection
 Figure 2. Bupivacaine Extended-Release Liposome Injection Report Years Considered
 Figure 3. Research Objectives
 Figure 4. Research Methodology
 Figure 5. Research Process and Data Source
 Figure 6. Global Bupivacaine Extended-Release Liposome Injection Sales Growth Rate 2020-2031 (K Units)
 Figure 7. Global Bupivacaine Extended-Release Liposome Injection Revenue Growth Rate 2020-2031 ($ millions)
 Figure 8. Bupivacaine Extended-Release Liposome Injection Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Figure 9. Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country/Region (2024)
 Figure 10. Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country/Region (2020, 2024 & 2031)
 Figure 11. Product Picture of 133mg Per Vial
 Figure 12. Product Picture of 266mg Per Vial
 Figure 13. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type in 2025
 Figure 14. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Type (2020-2025)
 Figure 15. Bupivacaine Extended-Release Liposome Injection Consumed in Local Anesthesia
 Figure 16. Global Bupivacaine Extended-Release Liposome Injection Market: Local Anesthesia (2020-2025) & (K Units)
 Figure 17. Bupivacaine Extended-Release Liposome Injection Consumed in Postoperative Analgesia
 Figure 18. Global Bupivacaine Extended-Release Liposome Injection Market: Postoperative Analgesia (2020-2025) & (K Units)
 Figure 19. Bupivacaine Extended-Release Liposome Injection Consumed in Other
 Figure 20. Global Bupivacaine Extended-Release Liposome Injection Market: Other (2020-2025) & (K Units)
 Figure 21. Global Bupivacaine Extended-Release Liposome Injection Sale Market Share by Application (2024)
 Figure 22. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Application in 2025
 Figure 23. Bupivacaine Extended-Release Liposome Injection Sales by Company in 2025 (K Units)
 Figure 24. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Company in 2025
 Figure 25. Bupivacaine Extended-Release Liposome Injection Revenue by Company in 2025 ($ millions)
 Figure 26. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Company in 2025
 Figure 27. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Geographic Region (2020-2025)
 Figure 28. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Geographic Region in 2025
 Figure 29. Americas Bupivacaine Extended-Release Liposome Injection Sales 2020-2025 (K Units)
 Figure 30. Americas Bupivacaine Extended-Release Liposome Injection Revenue 2020-2025 ($ millions)
 Figure 31. APAC Bupivacaine Extended-Release Liposome Injection Sales 2020-2025 (K Units)
 Figure 32. APAC Bupivacaine Extended-Release Liposome Injection Revenue 2020-2025 ($ millions)
 Figure 33. Europe Bupivacaine Extended-Release Liposome Injection Sales 2020-2025 (K Units)
 Figure 34. Europe Bupivacaine Extended-Release Liposome Injection Revenue 2020-2025 ($ millions)
 Figure 35. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales 2020-2025 (K Units)
 Figure 36. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Revenue 2020-2025 ($ millions)
 Figure 37. Americas Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country in 2025
 Figure 38. Americas Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Country (2020-2025)
 Figure 39. Americas Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2025)
 Figure 40. Americas Bupivacaine Extended-Release Liposome Injection Sales Market Share by Application (2020-2025)
 Figure 41. United States Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 42. Canada Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 43. Mexico Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 44. Brazil Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 45. APAC Bupivacaine Extended-Release Liposome Injection Sales Market Share by Region in 2025
 Figure 46. APAC Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Region (2020-2025)
 Figure 47. APAC Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2025)
 Figure 48. APAC Bupivacaine Extended-Release Liposome Injection Sales Market Share by Application (2020-2025)
 Figure 49. China Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 50. Japan Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 51. South Korea Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 52. Southeast Asia Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 53. India Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 54. Australia Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 55. China Taiwan Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 56. Europe Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country in 2025
 Figure 57. Europe Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Country (2020-2025)
 Figure 58. Europe Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2025)
 Figure 59. Europe Bupivacaine Extended-Release Liposome Injection Sales Market Share by Application (2020-2025)
 Figure 60. Germany Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 61. France Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 62. UK Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 63. Italy Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 64. Russia Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 65. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Market Share by Country (2020-2025)
 Figure 66. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2025)
 Figure 67. Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Market Share by Application (2020-2025)
 Figure 68. Egypt Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 69. South Africa Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 70. Israel Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 71. Turkey Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 72. GCC Countries Bupivacaine Extended-Release Liposome Injection Revenue Growth 2020-2025 ($ millions)
 Figure 73. Manufacturing Cost Structure Analysis of Bupivacaine Extended-Release Liposome Injection in 2025
 Figure 74. Manufacturing Process Analysis of Bupivacaine Extended-Release Liposome Injection
 Figure 75. Industry Chain Structure of Bupivacaine Extended-Release Liposome Injection
 Figure 76. Channels of Distribution
 Figure 77. Global Bupivacaine Extended-Release Liposome Injection Sales Market Forecast by Region (2026-2031)
 Figure 78. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share Forecast by Region (2026-2031)
 Figure 79. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share Forecast by Type (2026-2031)
 Figure 80. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share Forecast by Type (2026-2031)
 Figure 81. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share Forecast by Application (2026-2031)
 Figure 82. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share Forecast by Application (2026-2031)

Companies Mentioned

Pacira Pharmaceuticals

Jiangsu Hengrui Pharm

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff